查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586052

癌症免疫療法藥物發現外包市場：按癌症類型、藥物類型和服務類型 - 2025-2030 年全球預測

Cancer Immunotherapy Drug Discovery Outsourcing Market by Cancer Type (Breast, Colorectal, Head and Neck), Drug Type (Immunomodulators, Monoclonal Antibodies, Oncolytic Viral Therapies & Cancer Vaccines), Service Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症免疫治療藥物發現外包市場價值為16億美元，預計2024年將達到18.4億美元，複合年成長率為15.59%，到2030年將達到44.1億美元，預計將達到1000萬美元。

在癌症免疫治療的藥物發現外包中，藥物開發的各個階段，從研發到臨床試驗，皆委託給外部專業機構。該策略幫助製藥公司簡化流程、降低成本，並利用他們內部不具備的先進技術和專業知識。癌症免疫治療科學知識和技術的快速發展推動了藥物發現外包的需求，這需要公司不斷創新以保持競爭力。主要研究應用包括單株抗體、查核點抑制劑、癌症疫苗、細胞療法和細胞激素，最終用途廣泛，包括製藥公司、生技公司、研究機構和委外研發機構(CRO)。

主要市場統計
基準年[2023] 16億美元
預測年份 [2024] 18.4億美元
預測年份 [2030] 44.1億美元
複合年成長率（%） 15.59%

根據市場洞察，癌症患者數量的增加、免疫療法的創新以及個人化醫療的推動等趨勢推動了外包產業的發展。外包對於處理藥物發現和開發過程的複雜性並有效滿足監管要求至關重要。旨在共享專業知識和資源的策略聯盟和聯合研究也在增加。然而，資料安全問題、合作夥伴之間不同的品質標準以及嚴格的法規環境等挑戰可能會阻礙成長。此外，在保持開放溝通的同時不斷審查成本和收益的需要也會影響市場動態。

創新的機會在於先進的生物資訊學，以加速目標識別和增強的生物模擬技術，以最佳化藥物測試步驟。使用人工智慧和機器學習進行藥物發現的預測和最佳化具有巨大的成長潛力。市場的性質變得越來越適應性，重點是具有客製化監管和開發策略的利基治療方法和產品。公司可以透過利用這些技術進步並促進與學術機構和 CRO 的夥伴關係來受益。在這些情況下，投資安全、強大的資料管理工具和透明的溝通管道對於克服市場挑戰和利用成長機會至關重要。

市場動態：快速發展的癌症免疫療法藥物發現外包市場的關鍵市場洞察

供需的動態交互作用正在改變癌症免疫療法藥物發現外包市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球癌症發生率上升
    • 提高醫生和病人對免疫治療的認知
    • 增加對癌症治療開發的投資
  • 市場限制因素
    • 藥物開發和治療成本高昂
  • 市場機會
    • 增加有效癌症免疫療法開發的臨床試驗
    • 增加與製藥公司的 CDMO 合作夥伴關係
  • 市場挑戰
    • 嚴格的政府法規和指導方針

波特五力：引領癌症免疫療法藥物發現外包市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解癌症免疫療法藥物發現外包市場的外部影響

外部宏觀環境因素在塑造癌症免疫療法藥物發現外包市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解癌症免疫治療藥物發現外包市場的競爭狀況

癌症免疫療法藥物發現外包市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣供應商在癌症免疫治療藥物發現外包市場的績效評估

FPNV定位矩陣是評估癌症免疫療法藥物發現外包市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製癌症免疫療法藥物發現外包市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對癌症免疫治療藥物發現外包市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率正在上升
      • 提高醫生和病人對免疫治療的認知
      • 增加對癌症治療開發的投資
    • 抑制因素
      • 藥物開發和治療高成本
    • 機會
      • 增加臨床試驗以開發有效的癌症免疫療法
      • 擴大與製藥公司的 CDMO 合作
    • 任務
      • 嚴格的政府法規和指導方針
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章以癌症類型分類的癌症免疫治療藥物發現外包市場

  • 胸部
  • 冒號
  • 頭部和頸部
  • 肺
  • 惡性黑色素瘤
  • 卵巢
  • 胰臟
  • 攝護腺

第7章按藥物類型分類的癌症免疫治療藥物發現外包市場

  • 免疫調節劑
  • 單株抗體
  • 溶瘤病毒療法和癌症疫苗

第8章癌症免疫治療藥物發現外包市場：依服務類型

  • 基於細胞的檢測
  • 鉛篩檢與表徵
  • 目標識別與檢驗

第9章北美和南美癌症免疫療法藥物發現外包市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區癌症免疫治療藥物發現外包市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲癌症免疫療法藥物發現外包市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Inc.
  • Dalton Pharma Services
  • DiscoverX Corporation
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • Genscript Biotech Corporation
  • HD Biosciences Co., Ltd.
  • Horizon Discovery Group PLC
  • ImmunXperts SA
  • Jubilant Life Sciences Limited
  • Labcorp
  • Oncodesign Precision Medicine Opm SA
  • Personalis, Inc.
  • Promega Corporation
  • STC Biologics Inc.
  • TCG Lifesciences Pvt. Limited
  • WuXi AppTec Co., Ltd.
Product Code: MRR-205091A88709

The Cancer Immunotherapy Drug Discovery Outsourcing Market was valued at USD 1.60 billion in 2023, expected to reach USD 1.84 billion in 2024, and is projected to grow at a CAGR of 15.59%, to USD 4.41 billion by 2030.

Cancer immunotherapy drug discovery outsourcing involves delegating various stages of drug development-from research and development to clinical trials-to specialized external entities. This strategy helps pharmaceutical companies streamline processes, reduce costs, and access advanced technologies and expertise that might not be available in-house. The necessity of outsourcing in drug discovery is driven by the rapid evolution of scientific knowledge and technology related to cancer immunotherapy, where companies need to innovate continuously to remain competitive. Applications primarily include monoclonal antibodies, checkpoint inhibitors, cancer vaccines, cell therapies, and cytokines, with end-use sectors spanning pharmaceutical and biotechnology firms, research institutes, and contract research organizations (CROs).

KEY MARKET STATISTICS
Base Year [2023] USD 1.60 billion
Estimated Year [2024] USD 1.84 billion
Forecast Year [2030] USD 4.41 billion
CAGR (%) 15.59%

Market insights reveal that the outsourcing sector is buoyed by trends such as the escalation in cancer cases, innovations in immunotherapy treatments, and the push for personalized medicine. Outsourcing becomes essential to handle complexities in drug discovery and development processes, as well as to address regulatory demands efficiently. An increase in strategic alliances and collaborations can also be seen, aiming to pool expertise and resources. However, challenges such as data security concerns, variability in quality standards across partners, and stringent regulatory environments can impede growth. Moreover, the necessity to continuously scrutinize costs and benefits while maintaining open communication can affect market dynamics.

Innovation opportunities lie in advanced bioinformatics-which expedites target identification-and enhanced biosimulation techniques that optimize drug testing phases. Leveraging artificial intelligence and machine learning for predictions and optimization in drug discovery offers significant growth potential. The nature of the market is becoming increasingly adaptive, focusing on niche therapies and products with tailored regulatory and development strategies. Companies would benefit from leveraging these technological advancements and fostering partnerships with academia and CROs, where investing in secure, robust data management tools and transparent communication channels will be crucial to navigate market challenges and capitalize on growth opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Immunotherapy Drug Discovery Outsourcing Market

The Cancer Immunotherapy Drug Discovery Outsourcing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer globally
    • Increasing awareness regarding immunotherapy among physicians and patients
    • Increasing investments for the development of cancer therapies
  • Market Restraints
    • High cost of drug development and treatment
  • Market Opportunities
    • Rise in clinical trials for development of efficient cancer immunotherapy
    • Increasing CDMO collaborations with pharmaceutical companies
  • Market Challenges
    • Stringent government regulations and guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Immunotherapy Drug Discovery Outsourcing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Immunotherapy Drug Discovery Outsourcing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Immunotherapy Drug Discovery Outsourcing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Immunotherapy Drug Discovery Outsourcing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Immunotherapy Drug Discovery Outsourcing Market

A detailed market share analysis in the Cancer Immunotherapy Drug Discovery Outsourcing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Immunotherapy Drug Discovery Outsourcing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Immunotherapy Drug Discovery Outsourcing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Immunotherapy Drug Discovery Outsourcing Market

A strategic analysis of the Cancer Immunotherapy Drug Discovery Outsourcing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Immunotherapy Drug Discovery Outsourcing Market, highlighting leading vendors and their innovative profiles. These include BPS Bioscience, Inc., Celentyx Ltd., Charles River Laboratories International, Inc., Covance, Inc., Crown Bioscience, Inc., Curia Inc., Dalton Pharma Services, DiscoverX Corporation, Eurofins Scientific, Evotec SE, Explicyte, Genscript Biotech Corporation, HD Biosciences Co., Ltd., Horizon Discovery Group PLC, ImmunXperts SA, Jubilant Life Sciences Limited, Labcorp, Oncodesign Precision Medicine Opm SA, Personalis, Inc., Promega Corporation, STC Biologics Inc., TCG Lifesciences Pvt. Limited, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Immunotherapy Drug Discovery Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cancer Type, market is studied across Breast, Colorectal, Head and Neck, Lung, Melanoma, Ovarian, Pancreatic, and Prostate.
  • Based on Drug Type, market is studied across Immunomodulators, Monoclonal Antibodies, and Oncolytic Viral Therapies & Cancer Vaccines.
  • Based on Service Type, market is studied across Cell-based Assays, Lead Screening & Characterization, and Target Identification & Validation.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally
      • 5.1.1.2. Increasing awareness regarding immunotherapy among physicians and patients
      • 5.1.1.3. Increasing investments for the development of cancer therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of drug development and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in clinical trials for development of efficient cancer immunotherapy
      • 5.1.3.2. Increasing CDMO collaborations with pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and guidelines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Breast
  • 6.3. Colorectal
  • 6.4. Head and Neck
  • 6.5. Lung
  • 6.6. Melanoma
  • 6.7. Ovarian
  • 6.8. Pancreatic
  • 6.9. Prostate

7. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Immunomodulators
  • 7.3. Monoclonal Antibodies
  • 7.4. Oncolytic Viral Therapies & Cancer Vaccines

8. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type

  • 8.1. Introduction
  • 8.2. Cell-based Assays
  • 8.3. Lead Screening & Characterization
  • 8.4. Target Identification & Validation

9. Americas Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Drug Discovery Outsourcing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. BPS Bioscience, Inc.
  • 2. Celentyx Ltd.
  • 3. Charles River Laboratories International, Inc.
  • 4. Covance, Inc.
  • 5. Crown Bioscience, Inc.
  • 6. Curia Inc.
  • 7. Dalton Pharma Services
  • 8. DiscoverX Corporation
  • 9. Eurofins Scientific
  • 10. Evotec SE
  • 11. Explicyte
  • 12. Genscript Biotech Corporation
  • 13. HD Biosciences Co., Ltd.
  • 14. Horizon Discovery Group PLC
  • 15. ImmunXperts SA
  • 16. Jubilant Life Sciences Limited
  • 17. Labcorp
  • 18. Oncodesign Precision Medicine Opm SA
  • 19. Personalis, Inc.
  • 20. Promega Corporation
  • 21. STC Biologics Inc.
  • 22. TCG Lifesciences Pvt. Limited
  • 23. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BREAST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLORECTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEAD AND NECK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OVARIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PANCREATIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROSTATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRAL THERAPIES & CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CELL-BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD SCREENING & CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2023